Skip to main content
Premium Trial:

Request an Annual Quote

Nucleix Raises $55M in Financing Round

NEW YORK – Israeli liquid biopsy startup Nucleix said on Wednesday that it has raised $55 million in an oversubscribed financing round.

The Rehovot-based firm will use the funds to continue development of its EpiCheck methylation platform and to develop its Lung EpiCheck assay for the early detection of lung cancer.

The round was led by RA Capital Management and included participation from new investors Blackrock, Lilly Asia Ventures, Lyfe Capital and MILFAM Investments. Existing investors OrbiMed, Aurum Ventures, DSC Investment, OCI Bio Investments, and Zohar Zisapel also participated in the round.

Nucleix's EpiCheck platform searches for specific methylation patterns on circulating tumor DNA in a patient's blood or urine sample. The firm will use the platform in combination with next-generation sequencing to identify new biomarkers that can be used for early detection and monitoring of different cancer types. The firm believes EpiCheck can also be used in tandem with PCR to run cost-effective analyses in both centralized and local labs. 

Lung EpiCheck, Nucleix's early-stage lung cancer diagnostic, analyzes disease-specific changes in DNA methylation markers in blood samples from current and past smokers. The firm plans to launch a prospective study to validate Lung EpiCheck and anticipates offering the assay in 2022.

For an in-depth look on Nucleix's near-term plans, click here. 

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.